At the RNA Biology Lab, our research focuses on developing innovative CRISPR-Cas-based diagnostic and therapeutic solutions for genetic disorders, with a primary emphasis on Sickle Cell Anemia (SCA). We are pioneering the use of FnCas9 in gene editing and diagnostics, leveraging its high specificity and sensitivity for precise mutation detection and correction. Our team is dedicated to advancing ex vivo gene therapy approaches, including reprogramming patient-derived peripheral blood mononuclear cells (PBMCs) into induced pluripotent stem cells (iPSCs) and performing targeted gene correction. In collaboration with national and international clinical and research partners, we aim to develop affordable, rapid, and effective genetic tools to revolutionize patient care and provide long-term solutions for hereditary blood disorders.